A topical formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast is potentially effective in the treatment of plaque psoriasis, according to US researchers. Results from a phase 2b randomised controlled trial involving 331 adults with plaque psoriasis found that patients assigned to treatment with roflumilast cream showed significant improvements in psoriasis signs and symptoms within two ...
Topical PDE-4 inhibitor roflumilast shows promise in psoriasis
By Michael Woodhead
15 Jul 2020